Skip to main navigation Skip to search Skip to main content

Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial

  • Alon Eisen
  • , Robert P. Giugliano
  • , Christian T. Ruff
  • , Francesco Nordio
  • , Harinder S. Gogia
  • , Vivek R. Awasty
  • , David A. Henderson
  • , Michele F. Mercuri
  • , Howard Rutman
  • , Elliott M. Antman
  • , Eugene Braunwald

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science